Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw an 11.85% increase on Wednesday, reaching $4.91 per share. Jim Cramer recommended buying the stock on Mad Money, emphasizing its potential with backing from Nvidia and advancements in artificial intelligence for drug approvals.